Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement
- PMID: 23761782
- PMCID: PMC3671347
- DOI: 10.3389/fendo.2013.00064
Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement
Abstract
Deficiency of growth hormone (GH) in adults results in a syndrome characterized by decreased muscle mass and exercise capacity, increased visceral fat, impaired quality of life, unfavorable alterations in lipid profile and markers of cardiovascular risk, decrease in bone mass and integrity, and increased mortality. When dosed appropriately, GH replacement therapy (GHRT) is well tolerated, with a low incidence of side effects, and improves most of the alterations observed in GH deficiency (GHD); beneficial effects on mortality, cardiovascular events, and fracture rates, however, remain to be conclusively demonstrated. The potential of GH to act as a mitogen has resulted in concern over the possibility of increased de novo tumors or recurrence of pre-existing malignancies in individuals treated with GH. Though studies of adults who received GHRT in childhood have produced conflicting reports in this regard, long-term surveillance of adult GHRT has not demonstrated increased cancer risk or mortality.
Keywords: IGF-I; adult growth hormone deficiency; growth hormone; growth hormone risks; growth hormone treatment; insulin-like growth factor-I.
References
-
- Aimaretti G., Corneli G., Razzore P., Bellone S., Baffoni C., Arvat E., Etalname A. (1998). Comparison between insulin induced hypoglycemia and growth hormone (GH) releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. J. Clin. Endocrinol. Metab. 83, 1615–161810.1210/jc.83.5.1615 - DOI - PubMed
-
- al-Shoumer K. A., Gray R., Anyaoku V., Hughes C., Beshyah S., Richmond W., et al. (1998). Effects of four years’ treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin. Endocrinol. (Oxf.) 48, 795–80210.1046/j.1365-2265.1998.00460.x - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
